Sciomics‘ Impact on Proteomic Research

Please find below selected patents with contribution of our scioDiscover microarray platform.

Selected Patents

WO2021175863A1: Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer
WO2021162554A1: Means and methods for determining mesenchymal stromal cell properties.
US20210137912A1: s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid for use in medicine
EP2536844B1, US9551035B2: Means and methods for diagnosing pancreatic cancer
EP2718720B1, US9678075B2: Prediction of recurrence for bladder cancer by a protein signature in tissue samples

Subcategories

Proteomics Research Blog

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we have launched the Sciomics science blog!
Publications

Find peer-reviewed scientific publications on biomedical studies supported by our antibody microarray platform, scientific publications on the platform itself, information on poster presentations at international conferences and patents supported by Sciomics services.

scioDiscover: high-content protein profiling of 1,500 proteins

scioDiscover - In depth profiling on the protein level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay. Features Screen…

scioPhospho: phosphoproteomics and protein profiling service

Discover protein abundance and phosphorylation analysis in one step by our high-throughput scioPhospho platform. Simultaneous detection of protein levels & phosphorylation status of > 1,500 proteins. Our scioPhospho protein phosphorylation…

scioCD - Cell Surface Marker and Cytokine Profiling

Immune response profiling Cellular composition and signalling CD-Marker Expression Profiles Our scioCD profiling service covers 349 different proteins : up to 141 unique CD-marker molecules up to 119 cytokines and chemokines

scioCyto : Cytokine Profiling

scioCyto is a high-content analysis service for a multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell culture supernatants can be screened in a high sensitivity and reproducibility

Article | Exploration of Novel Biomarkers for Neurodegenerative Diseases

| December 2024 | Biomarker candidates for neurodegenerative diseases were identified by combining an exploratory proteomic approach with quantitative ligand-binding assays. Sciomics supported this study by proteomic screening of plasma and CSF samples of patients with different neurodegenerative diseases using the scioDiscover microarray platform.

Kenzelmann A, et al.. Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays. Biomedicines. 2024;12(12):2794.

Article | Altered Serum Proteins indicate Inflammation, Fibrogenesis and Angiogenesis in Fontan Patients

| September 2024 | Four identified serum proteins may advance diagnostic and therapeutic approaches by complementing traditional diagnostic laboratory variables. Sciomics contributed to this study by a scioCD serum analysis targeting different CD surface markers, cytokines and chemokines.

Michel M, Renaud D, Schmidt R, et al. Altered Serum Proteins Suggest Inflammation, Fibrogenesis and Angiogenesis in Adult Patients with a Fontan Circulation. International Journal of Molecular Sciences. 2024; 25(10):5416.

Article | Vago-splenic signal transduction of cardioprotection in humans

| April 2024 | The spleen as a relay organ as well as the vagal innervation determine cardioprotective signal transduction of Remote Ischaemic Conditioning (RIC) and Auricular Tragus Stimulation (ATS). Sciomics contributed to this study by analysing plasma-dialysate samples using the scioDiscover microarray platform.

Lieder HR, Paket U, Skyschally A, et al. Vago-splenic signal transduction of cardioprotection in humans. Eur Heart J. 2024;45(34):3164-3177.

Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023).

Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

Fiedler et al. Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes via PLP Cofactor Mimics (2023) ACS Chem Biol.

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

COVID-19 Biomarker

Proteomics Research Blog